ARANESP
AMGEN
Identification
- Active ingredient (INN)
- DARBEPOETINE ALFA
- Internal code
- 12 L 178
- Country of Origin
- Netherlands
- Pharmaceutical form
- SC/IV Injectable Solution (Pre-filled Syringe)
- Prescription List
- Highly Regulated (List I)
- Packaging
- b/04 seringues preremplies de 0.3ml avec syst. de securite ; b/04 seringues preremplies de 0.3ml sans syst. de securite ; b/01 seringue preremplie de 0.6ml avec syst. de securite ; b/01 seringue preremplie de 0.6ml sans syst. de securite ; b/01 seringue preremplie de 1.0ml avec syst. de securite ; b/01 seringue preremplie de 1.0ml sans syst. de securite ;
DAWA Clinical Workbench v2.0
Information may not be accurate. Always consult a physician, pharmacist, or specialist before acting on any data shown here.
Description
Human erythropoietin with 2 aa substitutions to enhance glycosylation (5 N-linked chains), 165 residues (MW=37 kD).
Produced in
Chinese hamster ovary (CHO) cells by recombinant DNA technology.
Indications
For the treatment of anemia (from renal transplants or certain HIV treatment)
Pharmacodynamics
Darbepoetin alfa is used in the treatment of anemia.
It is involved in the regulation of erythrocyte differentiation and the maintenance of a physiological level of circulating erythrocyte mass.
Adverse Effects
Improve decision support & research outcomes With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
View sample adverse effects data in our new Data Library! See the data Improve decision support & research outcomes with our structured adverse effects data.